{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:39Z","timestamp":1786725759258,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>Cancer represents a significant public health challenge and a leading cause of mortality globally. Quinazolinones represent a class of privileged structures that exhibit a broad spectrum of biological activities such as anticancer, antihypertensive, antifungal, antibacterial, and anti-inflammatory properties. In the present study, the synthesis of quinazoline-quinazolinone hybrids as anticancer agents and their cytotoxic evaluation are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>\n                      Initial studies were done by molecular docking of five analogs of quinazoline- quinazolinone hybrids, erlotinib, and doxorubicin against the epidermal growth factor receptor. Treatment of 3-amino quinazolinone with 4-chloro-2-phenylquinazoline afforded final compounds by the nucleophilic substitution of the chloride with the amine of 3-amino quinazolinone derivatives. The cytotoxic effects of the final compounds were determined\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      against the MCF-7 cell line using the MTT assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>\n                      Compound\n                      <jats:bold>5b<\/jats:bold>\n                      (7-hydroxy-2-methyl-3-(2-phenylquinazolin-4-ylamino) quinazolin-4(3H)- one) showed the highest docking score of -10.1 kcal\/mol. Additionally, compound\n                      <jats:bold>5d<\/jats:bold>\n                      (2-methyl-7-nitro-3-(2- phenylquinazolin-4-ylamino) quinazolin-4(3H)-one) exhibited remarkable\n                      <jats:italic toggle=\"yes\">in-vitro<\/jats:italic>\n                      cytotoxic activity at 100 \u03bcM against the MCF-7 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>\n                      In the present study, quinazoline-quinazolinone hybrids were synthesized, and their cytotoxic effects on the MCF-7 cell line were evaluated. Among them, compound\n                      <jats:bold>5d<\/jats:bold>\n                      exhibited the most significant cytotoxic activity. The insertion of a nitro group at the 7 position of quinazolinone enhanced the cytotoxic efficacy against MCF-7 cells, likely attributable to electronic influences. Consequently, this compound could serve as a lead compound in the search for new classes of effective anticancer agents.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/rps.rps_150_24","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:00:59Z","timestamp":1778479259000},"page":"375-385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Molecular docking, synthesis, and cytotoxic evaluation of novel quinazoline-quinazolinone hybrid compounds"],"prefix":"10.4103","volume":"21","author":[{"given":"Majid","family":"Azarmi","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hormozi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, Lorestan University of Medical Science, Khorramabad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezvan","family":"Rezaeinasab","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"R1-20260511","first-page":"5217","article-title":"Synthesis and cytotoxic activity of new pyrimido[1,2- c]quinazolines, [1,2,4]triazolo[4,3-c]quinazolines and (quinazolin-4-yl)-1H-pyrazoles hybrids","volume":"12","author":"Hawata","year":"2022","journal-title":"Biointerface Res Appl Chem."},{"key":"R2-20260511","first-page":"308","article-title":"Solvent-free synthesis and antimicrobial activity of dihydroquinazolinone derivatives","volume":"5","author":"Keikhosravi","year":"2022","journal-title":"J Med Chem Sci."},{"key":"R3-20260511","first-page":"69","article-title":"Synthesis and pharmacological evaluation of some new 1,2,4-triazolo quinazoline derivatives","volume":"64","author":"El-Shershaby","year":"2021","journal-title":"Az J Pharm Sci."},{"key":"R4-20260511","first-page":"4720,1","article-title":"et al","volume":"23","author":"Alqahtani","year":"2022","journal-title":"Cytotoxicity of newly synthesized quinazoline-sulfonamide derivatives in human leukemia cell lines and their effect on hematopoiesis in zebrafish embryos. Int J Mol Sci."},{"key":"R5-20260511","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1080\/14756366.2018.1510919","article-title":"Benzofuran-appended 4- aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies","volume":"33","author":"Mphahlele","year":"2018","journal-title":"J Enzyme Inhib Med Chem."},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"16134","DOI":"10.1021\/acsomega.8b01960","article-title":"Synthesis of triazole-substituted quinazoline hybrids for anticancer activity and a lead compound as the EGFR blocker and ROS inducer agent","volume":"3","author":"Banerji","year":"2018","journal-title":"ACS Omega."},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.2147\/DDDT.S209481","article-title":"Design, synthesis, and biological study of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia","volume":"13","author":"Cheng","year":"2019","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"R8-20260511","first-page":"1","article-title":"Synthesis, antimicrobial activity and molecular docking study of novel N,2-diphenylquinazolin-4-amine derivatives","volume":"19","author":"Seydbagian","year":"2023","journal-title":"Iran J Pharm Sci."},{"key":"R9-20260511","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/157018013804142447","article-title":"Synthesis and antiproliferative evaluation of hybrids of indolin-2-one and quinazoline-4(3H)-one linked via imine bond","volume":"10","author":"Wu","year":"2013","journal-title":"Lett Drug Des Discov."},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43094-020-00059-5","article-title":"Evaluation of antitumor potential of synthesized novel 2-substituted 4- anilinoquinazolines as quinazoline-pyrrole hybrids in MCF-7 human breast cancer cell line and A-549 human lung adenocarcinoma cell lines","volume":"6","author":"Bathula","year":"2020","journal-title":"Futur J Pharm Sci."},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/1735-5362.253360","article-title":"Synthesis and cytotoxic evaluation of some derivatives of triazolequinazolinone hybrids","volume":"14","author":"Hassanzadeh","year":"2019","journal-title":"Res Pharm Sci."},{"key":"R12-20260511","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/molecules25204780","article-title":"Synthesis, in silico and in vitro assessment of new quinazolinones as anticancer agents via potential AKT Inhibition","volume":"25","author":"Noser","year":"2020","journal-title":"Molecules."},{"issue":"5","key":"R13-20260511","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4103\/1735-5362.323919","article-title":"Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies","volume":"16","author":"Emami","year":"2021","journal-title":"Res Pharm Sci."},{"key":"R14-20260511","first-page":"1314461","article-title":"Design, synthesis, computational study and cytotoxic evaluation of some new quinazoline derivatives containing pyrimidine moiety","author":"Zare","year":"2023","journal-title":"Sci Rep."},{"issue":"2","key":"R15-20260511","first-page":"715","article-title":"In-silico determination of pKa and logp values of some isoniazid synthetic analogues using Marvin software","volume":"33","author":"Naeem","year":"2020","journal-title":"Pak J Pharm Sci."},{"issue":"3","key":"R16-20260511","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/1735-5362.228942","article-title":"Synthesis, antimicrobial evaluation and docking studies of some novel quinazolinone Schiff base derivatives","volume":"13","author":"Nasab","year":"2018","journal-title":"Res Pharm Sci."},{"key":"R17-20260511","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/1747519820910384","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives containing piperazine moieties as antitumor agents","volume":"44","author":"Li","year":"2020","journal-title":"J Chem Res."},{"key":"R18-20260511","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/1735-5362.268201","article-title":"Synthesis and cytotoxic evaluation of some quinazolinone- 5-(4- chlorophenyl) 1, 3, 4-oxadiazole conjugates","volume":"14","author":"Hassanzadeh","year":"2019","journal-title":"Res Pharm Sci."},{"key":"R19-20260511","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1747-0285.2011.01234.x","article-title":"Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives","volume":"78","author":"Wu","year":"2011","journal-title":"Chem Biol Drug Des."},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejmech.2015.04.037","article-title":"Synthesis and antitumor activities evaluation of m-(4- morpholinoquinazolin-2-yl)benzamides in vitro and in vivo","volume":"96","author":"Wang","year":"2015","journal-title":"Eur J Med Chem."},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"14685","DOI":"10.1038\/s41598-023-41283-2","article-title":"Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties","volume":"13","author":"Mortazavi","year":"2023","journal-title":"Sci Rep."},{"key":"R22-20260511","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1080\/14756366.2022.2118735","article-title":"Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity","volume":"37","author":"Sonousi","year":"2022","journal-title":"J Enzyme Inhib Med Chem."},{"key":"R23-20260511","doi-asserted-by":"crossref","first-page":"e26735","DOI":"10.1016\/j.heliyon.2024.e26735","article-title":"Synthesis, anticancer activity and molecular docking of new quinolines, quinazolines and 1,2,4-triazoles with pyrido[2,3-d] pyrimidines","volume":"10","author":"Abu-Hashem","year":"2024","journal-title":"Heliyon."},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"148","DOI":"10.9767\/bcrec.9.2.6794.148-154","article-title":"Selective solvent-free Biginelli condensation using tungstate sulfuric acid as powerful and reusable catalyst","volume":"9","author":"Nasab","year":"2014","journal-title":"Bull Chem React Eng Catal."},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/jrms.jrms_1025_21","article-title":"Quinazolinone-based hybrids with diverse biological activities: A mini-review","volume":"27","author":"Rezaeinasab","year":"2022","journal-title":"J Res Med Sci."},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/1735-5362.217425","article-title":"Synthesis, characterization, cytotoxic screening, and density functional theory studies of new derivatives of quinazolin-4(3H)-one Schiff bases","volume":"12","author":"Nasab","year":"2017","journal-title":"Res Pharm Sci."},{"key":"R27-20260511","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13065-024-01119-0","article-title":"Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations","volume":"18","author":"Masoudinia","year":"2024","journal-title":"BMC Chemistry."},{"key":"R28-20260511","doi-asserted-by":"crossref","first-page":"21340","DOI":"10.1039\/D2RA03684C","article-title":"Synthesis, antitumor activity, 3D-QSAR and molecular docking studies of new iodinated 4-(3H)-quinazolinones 3N- substituted","volume":"12","author":"Perez-Fehrmann","year":"2022","journal-title":"RSC Adv."},{"key":"R29-20260511","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin, an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells."},{"key":"R30-20260511","first-page":"669","article-title":"Design, synthesis and biological evaluation of some novel substituted quinazoline derivatives as antitumor agents","volume":"75","author":"Ahmed","year":"2018","journal-title":"Acta Pol Pharm."},{"key":"R31-20260511","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00044-020-02634-0","article-title":"Novel amide analogues of quinazoline carboxylate display selective anti-proliferative activity and potent EGFR inhibition","volume":"29","author":"Malhotra","year":"2020","journal-title":"Med Chem Res."},{"issue":"1","key":"R32-20260511","first-page":"e5","article-title":"One-pot synthesis, cytotoxic evaluation and molecular docking of 3,4,7,8-tetrahydroquinazoline- 2,5-(1H,6H)-dione derivatives on EGFR","volume":"5","author":"Rafian-boroujeni","year":"2022","journal-title":"Int Pharm Acta."}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_150_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:18Z","timestamp":1786724718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_150_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/rps.rps_150_24","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2024-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}